# Coagulation disorders and their cutaneous presentations: Diagnostic work-up and treatment

Ganary Dabiri, MD, PhD,<sup>a</sup> Elizabeth Damstetter, MD,<sup>b</sup> Yunyoung Chang, MD,<sup>b</sup> Emily Baiyee Ebot, MD,<sup>c</sup> Jennifer Gloeckner Powers, MD,<sup>d</sup> and Tania Phillips, MD<sup>b</sup> *Providence, Rhode Island; Boston, Massachusetts; and Nashville, Tennessee* 

#### Learning Objectives

After completing this learning activity, participants should be able to identify the indications for diagnostic testing for patients presenting with a cutaneous manifestation of an underlying coagulopathy and describe multidisciplinary treatment strategies for inherited and acquired coagulation disorders.

#### Disclosure: Editors

The editors involved with this CME activity and all content validation/peer reviewers of the journal-based CME activity have reported no relevant financial relationships with commercial interest(s).

#### Authors

The authors involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s).

#### Planners

The planners involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s). The editorial and education staff involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s).

Both inherited and acquired hypercoagulable states can present with nonspecific clinical manifestations, such as petechiae, purpura, livedo reticularis, and ulcerations. A good history and physical examination are crucial to diagnoses of these conditions. Inherited conditions tend to present either in neonatal period or later in life, while acquired conditions typically occur later in life. Diagnostic studies are performed to identify the coagulation cascade deficiency or defect. Treatment primarily hinges on anticoagulation and wound care. In this article, we provide an in-depth analysis of the clinical manifestations, diagnostic considerations, and management options of patients in hypercoagulable states. (J Am Acad Dermatol 2016;74:795-804.)

*Key words:* factor V Leiden mutation; hypercoagulable state; hyperhomocysteinemia; livedoid vasculopathy; protein C deficiency; protein S deficiency; thrombophilia; thrombosis; ulcers; warfarin necrosis.

The incidence of arterial and venous thromboses in patients in hypercoagulable states (HSs) is increased compared to the general population in spite of adequate preventive measures. In addition to macrovascular thromboses, HSs can lead to microvascular thrombi, leading to many nonspecific cutaneous manifestations, most notably ulcerations affecting the lower extremity (LE). However, ulcerations have many other causative etiologies that must be distinguished from a HS. Livedoid vasculopathy (LV) in the LEs is a major

Funding sources: None. Conflicts of interest: None declared. Accepted for publication August 19, 2015. distinguishing characteristic of patients with HSs. IV is characterized by recurrent reticulated purpura of the LEs with atrophie blanche (AB).<sup>1</sup> AB can be associated with IV, but also it can occur in the context of chronic venous insufficiency, further complicating the diagnostic picture. Many HSs have been linked to the development of LV (Table I). Here, we review the cutaneous manifestations of HSs and the vasculopathies most often encountered by the dermatologist in both the outpatient and inpatient settings.

© 2015 by the American Academy of Dermatology, Inc. http://dx.doi.org/10.1016/j.jaad.2015.08.071

Date of release: May 2016 Expiration date: May 2019

From the Department of Dermatology and Skin Surgery,<sup>a</sup> Roger Williams Medical Center/Boston University School of Medicine, Providence; Boston University School of Medicine,<sup>b</sup> Boston; Department of Hematology and Oncology,<sup>c</sup> University Medical Group, Providence; and Vanderbilt University Medical Center,<sup>d</sup> Nashville.

Reprint requests: Tania Phillips, MD, Department of Dermatology, Boston University School of Medicine, 725 Albany St, Ste 8B, Boston, MA 02118. E-mail: tphill@bu.edu. 0190-9622/\$36.00

J190-9022/330.00

AB:atrophie blancheAPC:activated protein CAPS:antiphospholipid syndromeAT:antithrombinATIIID:antithrombin III deficiencyDVT:deep vein thrombosisELISA:enzyme-linked immunosorbent assayFVL:factor V LeidenFVLM:factor V Leiden mutationHIT:heparin-induced thrombocytopeniaHS:hypercoagulable stateINR:international normalized ratioLE:lower extremityLMWH:low molecular weight heparinLV:livedoid vasculopathyPCR:polymerase chain reaction
APC:activated protein CAPS:antiphospholipid syndromeAT:antithrombinATIIID:antithrombin III deficiencyDVT:deep vein thrombosisELISA:enzyme-linked immunosorbent assayFVL:factor V LeidenFVLM:factor V Leiden mutationHIT:heparin-induced thrombocytopeniaHS:hypercoagulable stateINR:international normalized ratioLE:lower extremityLMWH:low molecular weight heparinLV:livedoid vasculopathyPCR:polymerase chain reaction
APS:antiphospholipid syndromeAT:antithrombinATIIID:antithrombin III deficiencyDVT:deep vein thrombosisELISA:enzyme-linked immunosorbent assayFVL:factor V LeidenFVLM:factor V Leiden mutationHIT:heparin-induced thrombocytopeniaHS:hypercoagulable stateINR:international normalized ratioLE:lower extremityLMWH:low molecular weight heparinLV:livedoid vasculopathyPCR:polymerase chain reaction
AT:antithrombinATIIID:antithrombin III deficiencyDVT:deep vein thrombosisELISA:enzyme-linked immunosorbent assayFVL:factor V LeidenFVLM:factor V Leiden mutationHIT:heparin-induced thrombocytopeniaHS:hypercoagulable stateINR:international normalized ratioLE:lower extremityLMWH:low molecular weight heparinLV:livedoid vasculopathyPCR:polymerase chain reaction
ATIIID:antithrombin III deficiencyDVT:deep vein thrombosisELISA:enzyme-linked immunosorbent assayFVL:factor V LeidenFVLM:factor V Leiden mutationHIT:heparin-induced thrombocytopeniaHS:hypercoagulable stateINR:international normalized ratioLE:lower extremityLMWH:low molecular weight heparinLV:livedoid vasculopathyPCR:polymerase chain reaction
DVT:deep vein thrombosisELISA:enzyme-linked immunosorbent assayFVL:factor V LeidenFVLM:factor V Leiden mutationHIT:heparin-induced thrombocytopeniaHS:hypercoagulable stateINR:international normalized ratioLE:lower extremityLMWH:low molecular weight heparinLV:livedoid vasculopathyPCR:polymerase chain reaction
ELISA:enzyme-linked immunosorbent assayFVL:factor V LeidenFVLM:factor V Leiden mutationHIT:heparin-induced thrombocytopeniaHS:hypercoagulable stateINR:international normalized ratioLE:lower extremityLMWH:low molecular weight heparinLV:livedoid vasculopathyPCR:polymerase chain reaction
FVL:factor V LeidenFVLM:factor V Leiden mutationHIT:heparin-induced thrombocytopeniaHS:hypercoagulable stateINR:international normalized ratioLE:lower extremityLMWH:low molecular weight heparinLV:livedoid vasculopathyPCR:polymerase chain reaction
FVLM:factor V Leiden mutationHIT:heparin-induced thrombocytopeniaHS:hypercoagulable stateINR:international normalized ratioLE:lower extremityLMWH:low molecular weight heparinIV:livedoid vasculopathyPCR:polymerase chain reaction
HIT:heparin-induced thrombocytopeniaHS:hypercoagulable stateINR:international normalized ratioLE:lower extremityLMWH:low molecular weight heparinLV:livedoid vasculopathyPCR:polymerase chain reaction
HS:hypercoagulable stateINR:international normalized ratioLE:lower extremityLMWH:low molecular weight heparinLV:livedoid vasculopathyPCR:polymerase chain reaction
INR:international normalized ratioLE:lower extremityLMWH:low molecular weight heparinLV:livedoid vasculopathyPCR:polymerase chain reaction
LE: lower extremity LMWH: low molecular weight heparin LV: livedoid vasculopathy PCR: polymerase chain reaction
LMWH: low molecular weight heparin LV: livedoid vasculopathy PCR: polymerase chain reaction
LV: livedoid vasculopathy PCR: polymerase chain reaction
PCR: polymerase chain reaction
P1: prothrombin time
PTT: partial thromboplastin time
SCD: sickle cell disease
TTP: thrombotic thrombocytopenia purpura
VTE: venous thromboembolism

# CUTANEOUS MANIFESTATIONS OF HYPERCOAGULABLE STATES Key points

- Identifying the different cutaneous presentation of hypercoagulable states
- Identifying the histology of livedoid vasculopathy

### Petechiae

Petechiae are pinpoint (≤3 mm), nonblanchable, erythematous macules that manifest as a result of erythrocyte extravasation from small cutaneous vessels. When nontraumatic, petechiae may herald thrombocytopenia, vasculitis, or concomitant anticoagulant therapy. Traumatic petechiae may appear marked relative to the degree of injury if platelets are low or if there is aberrant hemostasis. However, petechiae can appear after trauma or an acute elevation in intravascular pressure with normal platelets and hemostasis.<sup>2</sup> No additional diagnostic tests are usually necessary to identify petechiae. In certain scenarios, obtaining a skin biopsy specimen may help rule out an occult vasculitis. Additional work-up for thrombocytopenia may be warranted.

## Purpura

Purpura are nonblanchable, erythematous to violaceous macules or thin papules ranging in size from a few millimeters to several centimeters. Likewise, purpura imply erythrocyte extravasation from dermal or subcutaneous blood vessels.<sup>2</sup> The finding of "palpable purpura" is nondiagnostic, although palpable lesions are often indicative of a vasculitic disorder (Fig 1).<sup>3,4</sup> Both hypo- and hypercoagulable states may present with purpura

# Table I. Hypercoagulable states associated with livedoid vasculopathy\*

Factor V Leiden mutation Prothrombin G20210A mutation Protein C and protein S deficiency Antithrombin III deficiency Hyperhomocysteinemia Monoclonal cryoglobulinemia Hepatitis B and C, related to polyclonal cryoglobulins Cryofibrinogenemia Antiphospholipid antibodies

\*Adapted from Alavi et al.<sup>1</sup>

and can generally be distinguished by the history, physical examination, and basic laboratory tests (eg, partial thromboplastin time/prothrombin time). Hypocoagulable states often manifest as nonpalpable purpura (eg, ecchymoses) occurring at sites of trauma. HS are heralded by the appearance of retiform purpura, or stellate-appearing purpura with an incomplete net-like vascular background.<sup>2</sup> The differential diagnosis for retiform purpura is broad but implies a systemic disease process causing microvascular occlusion, and a thorough work-up must ensue.<sup>5</sup> A biopsy specimen of the skin may reveal features of vasculitis (ie, inflammation of vessel walls, erythrocyte extravasation, fibrinoid necrosis, or leukocytoclasia), vasculopathy (ie, vessel wall abnormalities without inflammation), or occlusion (ie, intraluminal thrombus or atherosclerosis).<sup>6</sup> Purpura fulminans-purpuric lesions that enlarge and become vesiculated-produce hemorrhagic bullae with subsequent necrosis and black eschar formation.

## Livedo reticularis

Livedo reticularis (LR) is an erythematous to violaceous, lacy, net-like, exaggerated venous pattern visible in states of slow venous flow (Fig 2). Classically, it presents on the lower extremities, is exacerbated in cold environments and, in idiopathic cases, reverses with warming the affected area, but once established the discoloration becomes permanent. Although LR may be a physiologic response to cold, in time LR may reflect an upstream occlusive process of arteries or arterioles, such as vasospasm or luminal obstruction (secondary LR). Neurologic disorders affecting vascular tone can also induce LR.<sup>2,6</sup>

Systemic work-up in patients with LR is guided by the history and physical examination.<sup>3,7,8</sup> The term livedo racemosa is used when the vascular patterns are fixed, the lacy pattern includes broken circles, and the patterns do not reverse with warming. This is considered an ominous sign of systemic disease.<sup>2</sup> A skin biopsy specimen obtained from the pale Download English Version:

# https://daneshyari.com/en/article/6069743

Download Persian Version:

https://daneshyari.com/article/6069743

Daneshyari.com